Online inquiry

IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ2747MR)

This product GTTS-WQ2747MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF11 gene. The antibody can be applied in Multiple myeloma (MM), Osteoporosis research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_003701.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	8600
UniProt ID	O14788

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2747MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ10224MR	IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	LFB-R593
GTTS-WQ1186MR	IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	ABP 501
GTTS-WQ12406MR	IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	NI-0401
GTTS-WQ12007MR	IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	MM-121
GTTS-WQ5863MR	IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	CHIR-12,12
GTTS-WQ8558MR	IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	Hu5F9-G4
GTTS-WQ11123MR	IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	MDX-1103
GTTS-WQ2171MR	IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	ALT-803

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST